99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate Cancer Patient, Responding to Modified Treatments.
{"title":"99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate Cancer Patient, Responding to Modified Treatments.","authors":"Nasrin Raeisi, Atena Aghaee, Kamran Aryana, Salman Soltani, Hamidreza Ghorbani","doi":"10.1097/RLU.0000000000005522","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>This case report presents a rare instance of pulmonary lymphangitic carcinomatosis (PLC) in a prostate cancer patient, showcasing uptake of 99mTc-prostate-specific membrane antigen and 99mTc-fibroblast activation protein inhibitor-46 on imaging scans. A 70-year-old man with elevated serum prostate-specific antigen (PSA) levels exhibited respiratory symptoms and was diagnosed with widespread skeletal and pulmonary metastases. Following taxane-based chemotherapy and androgen deprivation therapy, imaging revealed decreased uptake and improvement in clinical symptoms, indicating treatment response. PLC in prostate cancer is exceptionally rare, with only limited documented cases. This report highlights the diagnostic value of 99mTc-prostate-specific membrane antigen and 99mTc-fibroblast activation protein inhibitor scans in identifying PLC and monitoring treatment response, offering insights into the management of this challenging condition.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005522","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: This case report presents a rare instance of pulmonary lymphangitic carcinomatosis (PLC) in a prostate cancer patient, showcasing uptake of 99mTc-prostate-specific membrane antigen and 99mTc-fibroblast activation protein inhibitor-46 on imaging scans. A 70-year-old man with elevated serum prostate-specific antigen (PSA) levels exhibited respiratory symptoms and was diagnosed with widespread skeletal and pulmonary metastases. Following taxane-based chemotherapy and androgen deprivation therapy, imaging revealed decreased uptake and improvement in clinical symptoms, indicating treatment response. PLC in prostate cancer is exceptionally rare, with only limited documented cases. This report highlights the diagnostic value of 99mTc-prostate-specific membrane antigen and 99mTc-fibroblast activation protein inhibitor scans in identifying PLC and monitoring treatment response, offering insights into the management of this challenging condition.
期刊介绍：
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
